Screener
Stryker SYK Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| MedSurg and Neurotechnology: | $3.21B+4.9% | $4.56B+17.5% | $3.8B+14.4% | $3.77B+17.3% | $3.06B-1.3% | |
| Orthopaedics: | $2.81B+0.1% | $2.61B+2.2% | $2.25B+3.9% | $2.25B+2.0% | $2.81B+30.9% | |
| Net Sales by Product | ||||||
| Endoscopy | $868M+0.1% | $1.15B+13.8% | $896M+7.0% | $899M+17.1% | $867M+11.4% | |
| Hips | $460M+3.8% | $499M+7.8% | $457M+8.8% | $466M+8.9% | $443M+12.7% | |
| Instruments | $920M+9.8% | $925M+17.1% | $760M+11.9% | $768M+10.0% | $838M+25.6% | |
| Knees | $670M+4.9% | $749M+9.0% | $628M+10.2% | $640M+6.3% | $639M+8.7% | |
| Medical | $902M-4.6% | $1.28B+12.4% | $985M+5.0% | $990M+9.0% | $945M+9.4% | |
| Ortho Tech | $646M+4.7% | —— | —— | —— | $617M— | |
| Spine | $2M-98.8% | $8M-95.7% | $6M-96.5% | $5M-97.2% | $166M-2.9% | |
| Trauma and Extremities | $1.04B+9.5% | $1.09B+9.0% | $960M+13.1% | $957M+15.0% | $945M+13.9% | |
| Vascular | $517M+27.3% | $539M+58.1% | $525M+59.6% | $498M+52.3% | $406M+31.0% | |
| Net Sales by Geography | ||||||
| International | $1.54B+8.3% | $1.73B+10.7% | $1.49B+7.3% | $1.47B+6.8% | $1.43B+7.3% | |
| United States | $4.48B+0.8% | $5.44B+11.7% | $4.57B+11.2% | $4.55B+12.5% | $4.44B+13.4% |
FAQ
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
